Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Hansel

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Annual Review of Animal Biosciences|November 12, 2014
After 65 years, research is still funWilliam Hansel
Current Pharmaceutical Design|July 29, 2004
Membrane disrupting lytic peptides for cancer treatmentsCarola Leuschner, William Hansel
Biology of Reproduction|July 22, 2005
Targeting breast and prostate cancers through their hormone receptorsCarola Leuschner, William Hansel
Molecular and Cellular Endocrinology|March 27, 2007
Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastasesWilliam Hansel, Carola Leuschner, Fred Enright
Molecular and Cellular Endocrinology|November 15, 2006
Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivoWilliam Hansel, Fred Enright, Carola Leuschner
Experimental Biology and Medicine (Maywood, N.J.)|October 8, 2003
Nitric oxide as a local mediator of prostaglandin F2alpha-induced regression in bovine corpus luteum: an in vivo studyJerzy J Jaroszewski, Dariusz J Skarzynski, William Hansel
Gynecologic Oncology|April 2, 2002
Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivoBarbara Gawronska, Carola Leuschner, Frederick M Enright, et al.
Breast Cancer Research and Treatment|March 4, 2003
Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivoCarola Leuschner, Frederick M Enright, Barbara Gawronska, et al.
The Prostate|July 15, 2003
Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptorsCarola Leuschner, Frederick M Enright, Barbara Gawronska-Kozak, et al.
Reproductive Biology|August 5, 2008
Immune response to lytic peptides conjugated to a betaCG fragment in treated BALB/C miceMarek Bogacki, Frederic M Enright, William J Todd, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Annual Review of Animal Biosciences|November 12, 2014
After 65 years, research is still funWilliam Hansel
Current Pharmaceutical Design|July 29, 2004
Membrane disrupting lytic peptides for cancer treatmentsCarola Leuschner, William Hansel
Biology of Reproduction|July 22, 2005
Targeting breast and prostate cancers through their hormone receptorsCarola Leuschner, William Hansel
Molecular and Cellular Endocrinology|March 27, 2007
Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastasesWilliam Hansel, Carola Leuschner, Fred Enright
Molecular and Cellular Endocrinology|November 15, 2006
Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivoWilliam Hansel, Fred Enright, Carola Leuschner
Experimental Biology and Medicine (Maywood, N.J.)|October 8, 2003
Nitric oxide as a local mediator of prostaglandin F2alpha-induced regression in bovine corpus luteum: an in vivo studyJerzy J Jaroszewski, Dariusz J Skarzynski, William Hansel
Gynecologic Oncology|April 2, 2002
Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivoBarbara Gawronska, Carola Leuschner, Frederick M Enright, et al.
Breast Cancer Research and Treatment|March 4, 2003
Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivoCarola Leuschner, Frederick M Enright, Barbara Gawronska, et al.
The Prostate|July 15, 2003
Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptorsCarola Leuschner, Frederick M Enright, Barbara Gawronska-Kozak, et al.
Reproductive Biology|August 5, 2008
Immune response to lytic peptides conjugated to a betaCG fragment in treated BALB/C miceMarek Bogacki, Frederic M Enright, William J Todd, et al.
Pageof 2